Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2025-03-13 00:00:00 ET · period of report 2025-03-12 · accession 0000950170-25-038801 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-13 | 2025-03-12 | DFTX | Barrow Robert | CEO, Dir | A - Grant | $0.00 | +350.0K | 877.8K | +66% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-03-12 | A | A | 350,000 | $0.00 | 877,764 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. (F2) Amount includes 1,098 shares acquired under the Mind Medicine (MindMed) Inc. 2024 Employee Share Purchase Plan on February 18, 2025. |